Intended for healthcare professionals

Editorials

Risk prediction in early triple negative breast cancer

BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2088 (Published 23 October 2024) Cite this as: BMJ 2024;387:q2088

Linked Research

Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature